Clinical trial
Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination…
NCT00002209 · Centaur Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00002209 |
|---|---|
| Title | Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy |
| Official title | Multiple Ascending Dose Pharmacokinetics of CPI-1189 (LU 02-584) in Fasted, HIV Infected, Male Volunteers on Combined Reverse Transcriptase and Protease Inhibitor Therapy |
| Lead sponsor | Centaur Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | AIDS Dementia Complex, HIV Infections |
| Intervention type | Drug |
| Interventions | CPI-1189 |
| Enrollment | 48 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: